# Progress Note 04 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN-TD
- Date: 1974-08-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Presley is a 39-year-old singer with opioid use disorder on buprenorphine, a benzodiazepine use disorder on a slow diazepam taper, stage 2 hypertension, obesity with prediabetes, obstructive sleep apnea on CPAP, opioid-induced constipation and glaucoma, who comes for his yearly preventive visit one week after his three-week review and five days before a Las Vegas engagement. He has taken buprenorphine 16 mg every morning without withdrawal and with few cravings. He took the first diazepam step, to 36 mg a day, a week ago and noticed only slightly worse sleep for two nights. He took his first tirzepatide dose a week ago and had mild nausea for a day. He uses CPAP most nights and feels more awake in the afternoon. His bowels open every one to two days. He has not had a tetanus booster in more than ten years and has never been tested for HIV or hepatitis. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 39 |
| Buprenorphine | 16 mg daily for four weeks; few cravings |
| Diazepam | 36 mg a day since one week ago |
| Tirzepatide | First 2.5 mg dose a week ago; mild nausea for a day |
| Mood | PHQ-9 5; item 9 scored 0 |
| Medicines | Buprenorphine with naloxone 16 mg daily; diazepam 36 mg a day; amlodipine with valsartan; tirzepatide 2.5 mg weekly; polyethylene glycol; latanoprost; naloxone spray on hand |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with him by Dr. Ashby-Nakagawa. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than a month ago |
| Psychosocial | Busy professional life; close friends who work with him; worried about how the engagement will go during treatment |
| Alcohol | None; AUDIT-C 0 |
| Tobacco | Never |
| Other substances | Only the medicines prescribed by this clinic since intake; DAST-10 7 at intake, now in treatment |
| Physical activity | Karate practice twice a week and walks on the grounds most days |
| Nutrition | Moving the main meal earlier; fewer late-night meals |
| Sleep | Seven to eight hours with CPAP; less afternoon sleepiness |
| Safety at home | Feels safe; firearms now locked and unloaded with ammunition separate |
| Road safety | Wears a seat belt; not driving himself until the sleepiness has resolved |
| Activities of daily living | Independent |
| Hearing and vision | Wears tinted glasses for light sensitivity; ophthalmology follow-up planned next month |
| Oral health | Dental visit in the past year |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight down 1.4 kg since intake |
| Eyes | Negative | No eye pain, halos or change in vision |
| Ears, nose, mouth, and throat | Negative | No dry mouth from CPAP |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness; snoring stopped on CPAP |
| Gastrointestinal | Positive | Mild nausea for a day after the first tirzepatide dose; bowels every one to two days |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Positive | Occasional neck and back stiffness after practice |
| Integumentary | Negative | No rash or injection-site reaction |
| Neurological | Negative | No tremor, headaches or numbness |
| Psychiatric | Negative | PHQ-9 5; no thoughts of suicide or self-harm; cravings low |

11 systems reviewed. **S**

## Current medications

- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time **S**
- Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) **S**
- Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**
- Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/80 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 107.6 kg; BMI 32.1 kg/m². All vital signs are synthetic.

PHQ-9: 5; Total cholesterol: 214 mg/dL (high); HDL cholesterol: 38 mg/dL (low); LDL cholesterol (calculated): 140 mg/dL (high); Triglycerides: 180 mg/dL (high). All results are synthetic.

## Change since baseline

- PHQ-9: 8 at baseline, 5 at this visit **S**

## Immunizations given today

- Tdap vaccine; last tetanus booster more than ten years ago **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 107.6 kg, BMI 32.1; blood pressure 126/80; pulse 74 |
| Eyes | Pupils equal and reactive; no redness |
| Neck | Circumference 44 cm; no thyroid enlargement |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear |
| Abdomen | Soft, non-tender; liver edge not palpable; no distension |
| Skin | Injection site clean; no track marks |
| Neurological | Normal; no tremor |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Lipids: total cholesterol 214, HDL 38, LDL 140 and triglycerides 180 mg/dL, a pattern that fits obesity and prediabetes. At 39 the pooled cohort equations do not apply; his 10-year risk by the AHA PREVENT equations is low, so a statin is not indicated now, and weight loss, activity and blood pressure control are the main steps. **S**
   - Repeat lipids after six months of weight treatment.
   - HIV, hepatitis C and hepatitis B tests drawn today.
   - Next preventive visit in one year.
2. **Opioid use disorder on buprenorphine** (F11.20). Stable on 16 mg with few cravings. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the house and the tour bag; firearms locked. **S**
   - Prescriptions for the engagement sent to one named pharmacy in Las Vegas.
   - Weekly video visits while he is away.
3. **Obesity, class 1, with prediabetes** (E66.811). Weight down 1.4 kg since intake; tolerating the first tirzepatide dose. **S**
   - Continue tirzepatide 2.5 mg weekly.
   - Intensive behavioral counseling with a dietitian, by video during the engagement.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 126/80 mmHg on treatment; home average 128/82 |
| Lipid screening and cardiovascular risk | Completed today | Total cholesterol 214, HDL 38, LDL 140, triglycerides 180 mg/dL; low 10-year risk; statin not indicated at 39 |
| Diabetes screening | Up to date | Hemoglobin A1c 5.8% at intake, prediabetes; treated with weight loss |
| Obesity behavioral counseling | Completed today | BMI 32.1; intensive counseling with a dietitian arranged |
| Unhealthy drug use screening | Up to date | DAST-10 7 at intake; in treatment |
| Unhealthy alcohol use | Up to date | AUDIT-C 0 at intake |
| Tobacco use | Not indicated | Never used tobacco |
| Depression screening | Completed today | PHQ-9 5, item 9 scored 0 |
| HIV screening | Ordered | Once for all adults; drawn today with his agreement |
| Hepatitis C screening | Ordered | Once for all adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today |
| Colorectal cancer screening | Not indicated | Begins at 45 |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap given today; last booster more than ten years ago |
| Hepatitis B vaccine | Due | Recommended for adults 19 to 59; to start once today's serology shows he is not immune |
| Influenza vaccine | Due | When the autumn vaccine is available |
| COVID-19 vaccine | Due | Discussed under shared clinical decision-making; to decide in the autumn |
| Eye examination | Up to date | Under his ophthalmologist's care for glaucoma; next visit next month |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, a long-time friend who works with him, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being able to sing and to be there for the people who depend on him, and that he would want full treatment, including resuscitation and breathing support, after an overdose or other sudden illness. The plan will be revisited yearly or after any serious illness. **S**

## Guideline basis

- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018), U.S. Preventive Services Task Force
- Unhealthy Drug Use: Screening (2020), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Las Vegas engagement with weekly video visits; ten-week review after he returns. HIV, hepatitis C and hepatitis B results by phone. Next preventive visit in one year. **S**
- Next scheduled visit 1974-09-23: ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour. **S**
